Donepezil for Huntington's disease

Movement Disorders

Volumn 15, Issue 1, 2000, Pages 173-176

  Fernandez, Hubert H ^a,b   Friedman, Joseph H ^a,b   Grace, Janet ^b   Beason Hazen, Suzanne ^b  

^a MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMFEBUTAMONE; ASCORBIC ACID; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; CLONAZEPAM; DONEPEZIL; FLUOXETINE; HALOPERIDOL; OLANZAPINE; SERTRALINE; THIORIDAZINE; TRAZODONE; VALPROIC ACID; VENLAFAXINE; VITAMIN B GROUP;

ADULT; AGED; ANOREXIA; ANXIETY NEUROSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; DIARRHEA; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; FALLING; FATIGUE; FEMALE; HUMAN; HUNTINGTON CHOREA; INVOLUNTARY MOVEMENT; IRRITABILITY; MALE; MOTOR PERFORMANCE; NAUSEA; NEUROPSYCHOLOGICAL TEST; PATIENT COMPLIANCE; PRIORITY JOURNAL; RATING SCALE; VOMITING;

ADULT; AGED; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; HUNTINGTON DISEASE; INDANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES;

EID: 0033976626     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(200001)15:1<173::AID-MDS1032>3.0.CO;2-T     Document Type: Article

References (16)

1. Goetz CG, Tanner CM, Cohen JA, et al. L-acetyl-carnitine in Huntington's disease: a double-blind placebo controlled crossover study of drug effects on movement disorder and dementia. Mov Disord 1990;5:263-265.
2. Murman DL, Giordani B, Mellow AM, et al. Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease. Neurology 1997;49:153-161.
3. Peyser CE, Folstein M, Chase GA, et al. Trial of d-alpha-tocopherol in Huntington's disease. Am J Psychiatry 1995;152: 1771-1775.
4. Shoulson I, Goldblatt D, Charlton M, Joynt RJ. Huntington's disease: treatment with muscimol, a GABA-mimetic drug. Ann Neurol 1978;4:279-284.
5. Davis KL, Berger PA. Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis. Biol Psychiatry 1978;13:23-49.
6. Nutt JG, Rosin A, Chase TN. Treatment of Huntington's disease with a cholinergic agonist. Neurology 1978;28:1061-1064.
7. Growdon JH, Cohen EL, Wurtman RJ. Huntington's disease: clinical and chemical effects of choline administration. Ann Neurol 1977;1:418-422.
8. Growdon JH. Effects of choline on tardive dyskinesia and other movement disorders. Psychopharmacol Bull 1978;14:55-56.
9. Tarsy D, Bralower M. Deanol acetamidobenzoate treatment in choreiform movement disorders. Arch Neurol 1977;34:756-758.
10. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:136-145.
11. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicenter open label extension study. Eur Neuropsychopharmacol 1998;8:67-75.
12. Wilkinson D. Clinical experience with donepezil (Aricept) in the UK. J Neural Transm Suppl 1998;54:311-315.
13. Geizer M, Ancill RJ. Combination of risperidone and donepezil in Lewy body dementia. Can J Psychiatry 1998;43:421-422.
14. Taverni JP, Seliger G, Lichtman SW. Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation. Brain Inj 1998;12:77-80.
15. Shea C, MacKnight C, Rockwood K. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 1998;10:229-238.
16. Kaufer DI, Catt KE, Lopez OL, DeKosky ST. Dementia with Lewy bodies: response of delirium-like features to donepezil. Neurology 1998;51:1512.